It seems that no one in policy circles believes that people respond to incentives. How else can we explain this lengthy piece in the New York Times on the process by which the Food and Drug Administration (FDA)) approved Adehelm, a drug for treating Alzheimer’s disease. The piece details how the clinical trials designed to More
The post Patent Monopolies, Corruption, and the New Alzheimer’s Drug appeared first on CounterPunch.org.
This content originally appeared on CounterPunch.org and was authored by Dean Baker.